The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs.
After removal of the ovaries approximately 20% of dogs develop urinary incontinence. Removal of the gonads results in estrogen deficiency and chronic elevation in the production and secretion of FSH and LH. The gonadotrophins may directly or indirectly, adversely affect the sphincter function of the urethra. Estrogen replacement therapy and treatment with sympathomimetics, such as ephedrine or phenylpropanolamine (PPA), are effective only in some of the affected dogs, and many of these subsequently become nonresponsive. Since the role of the elevated gonadotrophins has not been elucidated, we used depot preparations of GnRH analogues to down-regulate gonadotrophins once or twice in 13 ovariectomized (ovx), incontinent dogs, which were either refractory to alpha-adrenergics (n=11) or in which alpha-adrenergics were contraindicated (n=2). Dogs were treated with leuprolide, deslorelin, buserelin or triptorelin. In 7 dogs treatments with GnRH analogues alone (n=11) resulted in continence for 50-738 days (mean 247). In all dogs except one, where GnRH treatments did not resolve the incontinence completely, additional treatment with phenylpropanolamine was successful. With additional treatment of phenylpropanolamine complete continence was restored for 21-367 days (mean 159). All treatments caused long-term reduction of circulating FSH and LH concentrations to very low or undetectable levels. No adverse effects of treatments were observed.
D000818:Animals; D002064:Buserelin / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D016729:Leuprolide / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000097:blood; D010052:Ovariectomy / Q000009:adverse effects / Q000662:veterinary*; D010665:Phenylpropanolamine / Q000008:administration & dosage; D013566:Sympathomimetics / Q000008:administration & dosage; D017329:Triptorelin Pamoate / Q000627:therapeutic use; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*
D013566:Sympathomimetics; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D010665:Phenylpropanolamine; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide; D002064:Buserelin